Catalyst

Slingshot members are tracking this event:

Johnson & Johnson (JNJ) subsidiary Janssen files EMA application for approval of Guselkumab in treating moderate to severe plaque psoriasis

Source Link:
http://files.shareholder.com/downloads/JNJ/4199603970x0x919155/89C65D42-B197-4654-B68C-3AB95DCFF091/Janssen_EMEA_UK_Guselkumab_Filing_Release_FINAL_11_24_16.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
JNJ Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 25, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Plaque Psoriasis, Ema, Guselkumab
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.